HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Molecular Marvel       » Biogas beats Bioethanol       » Brain 'switch' can Turn off Drug Addiction (Eye on China)       » Novel Imaging Technology REFI takes Clinicians closer to detecting Stage 0 Tumour Lesions (Eye on China)      
INSIDE INDUSTRY
Joslin Diabetes Center Forms Alliance with Johnson & Johnson Innovation to Identify Exercise-Related Drug Targets to Improve Diabetes Management
Joslin Diabetes Center announces a research and development alliance with Johnson & Johnson Innovation and its affiliate Janssen Research & Development, LLC, to identify and advance early-stage, novel therapeutic projects for potential for commercialization and product development. The first joint project selected in the alliance will focus on identifying exercise-related drug targets for developing new diabetes treatments.

“Joslin is uniquely positioned to translate findings in the laboratory into new approaches for treatment of diabetes, and our alliance with Johnson & Johnson Innovation and Janssen Research & Development is an excellent example of how we can move our early discoveries to the clinic with our complementary capabilities,” said Dr. Nandan Padukone, Ph.D., MBA, VP of Commercialization and Ventures at Joslin. “We will continue to explore other technologies with Johnson & Johnson Innovation and mechanisms such as venture creation to advance them quickly towards drug development.”

The new alliance is based on pioneering studies by Joslin researchers showing that exercise can train multiple tissues in the body that in turn stimulate metabolic improvements in other tissues. “The concept of tissue-to-tissue communication has been around for a while, but more recently we have realized that ‘trained’ tissues may communicate to beneficially affect other tissues,” said Laurie Goodyear, Ph.D., Co-Head of the Integrative Physiology and Metabolism Section at Joslin and senior investigator on this research presented earlier this year at the American Diabetes Association’s 73rd annual Scientific Sessions. “Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy